• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

EDITORIALI - Editorials

Volume:

Biochimica Clinica 2022; 46(1) e1-e3

Pubblicato on-line:

November 25, 2021

DOI:

10.19186/BC_2021.072

Scarica in PDF:
Autenticazione richiesta

Hematocrit interference in coagulation tests: what else can we do?

AUTORI

Nazaret Del Amo Del Arco, María Caballero Ruiz, Luz M. Cruz Carlos, María Dolade Botías, Silvia Pico Fornies, Raquel Guillén Santos, Mercè Ibarz Escuer, Isabel Llovet Lombarte, M Eugenia Marquez Beltrí, Francisco Javier Mérida de la Torre, E Elvira Moreno Compy, Judith Prieto Labiano, Marta Duque Alcorta
Committe for the Patient Safety of the Spanish Society of Laboratory Medicine (SEQCML), Spain

ABSTRACT

Hematocrit interference in coagulation tests: what else can we do?

The required blood to anti-coagulant ratio in the tubes for coagulation tests, is 9:1; any deviation from this ratio should be avoided as it may lead to erroneous analytical results. One of the variables influencing the ratio is an elevated hematocrit (>55%), because the elevated concentration of citrate in the plasma specimen can cause clotting times falsely increased. These erroneous results can lead to possible misdiagnosis, incorrect patient treatment and/or the performance of additional unnecessary investigations. We present the case of a 46-year-old man referred to the laboratory for a pre-surgery check. The presence of elevated values in his coagulation tests led to delayed surgery and to additional tests. Once the error was detected, a root cause analysis was performed. The main contributing factors to the pre-analytical error were identified using Ishikawa method; factors related to the organization, staff and environment were identified and analyzed. Preventive actions (safety barriers) were designed to prevent the error from recurring. The safety barriers implemented were: an automatic flag displayed in the information laboratory system (LIS) in cases of elevated hematocrit (>55%), to enhancement of the possible error detection plus additional laboratory staff training. At the best of our knowledge, since these safety barriers were applied three years ago, no coagulation test results interfered by high hematocrit have been released from our laboratory. This case demonstrates the importance of implementing safety barriers to prevent errors arising from situations that, although already described and well known, may go unnoticed by the laboratory staff

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967